多参数磁共振成像的生境成像在乳腺癌精准诊疗中的研究进展

Habitat imaging with multiparametric MRI in breast cancer precision medicine: recent advances

摘要

生境成像能够从细胞及分子水平表征肿瘤异质性，通过将肿瘤划分为具有同质性的生物学子区域，从而实现肿瘤异质性的空间可视化。近年来，基于多参数磁共振成像的生境成像技术在乳腺癌诊疗领域展现出重要临床应用价值，尤其是在预测乳腺癌分子亚型、淋巴结血管侵犯及新辅助治疗疗效等方面具有较高临床获益。本文综述了多模态磁共振成像的生境成像在乳腺癌诊疗中的应用现状及研究进展，分析当前研究的局限并展望未来发展方向，为深入理解生境成像在乳腺癌中的应用价值提供参考。

Abstract

Habitat Imaging enables the characterization of intratumoral heterogeneity at cellular and molecular levels by partitioning tumors into biologically homogeneous subregions, thereby achieving spatial visualization of heterogeneity of tumor. In recent years, multiparametric magnetic resonance imaging (MRI)-based habitat imaging technology has demonstrated significant clinical value in breast cancer diagnosis and treatment, particularly in predicting molecular subtypes, lymphovascular invasion and neoadjuvant therapy response with high clinical efficacy. This article reviewed the current applications of and research progress in multiparametric MRI-based habitat imaging in the diagnosis and treatment of breast cancer, analyzed the limitations of existing studies, and discussed future development directions, aiming to provide insights into the clinical value of habitat imaging in breast cancer.

关键词

多参数磁共振成像 / 生境成像 / 乳腺癌 / 肿瘤异质性 / 分子分型 / 淋巴血管浸润 / 新辅助治疗

Key words

multiparametric magnetic resonance imaging / habitat imaging / breast cancer / heterogeneity of tumor / molecular subtype / lymphovascular invasion / neoadjuvant therapy

参考文献

[1] XU C, WANG Z H, WANG A L, et al. Breast cancer: multi—b—value diffusion weighted habitat imaging in predicting pathologic complete response to neoadjuvant chemotherapy[J]. Academic radiology, 2024, 31(12): 4733-4742.

[2] KAZEROUNI A S, HORMUTH D A, DAVIS T, et al. Quantifying tumor heterogeneity via MRI habitats to characterize microenvironmental alterations in HER2+ breast cancer[J]. Cancers, 2022, 14(7): 1837.

[3] 刘嘉晨, 吴昊, 方靖琴, 等. 基于多参数MRI生境成像对胶质母细胞瘤评估的研究进展[J]. 国际医学放射学杂志, 2021, 44(4): 420-424.

[4] 焦凯剑, 杨波, 陈文, 等. 基于多模态MRI影像组学的胶质母细胞瘤生境亚区预测MGMT启动子甲基化表达[J]. 磁共振成像, 2023, 14(11): 25-30, 76.

[5] WU P Q, GUO F L, WANG J, et al. Development and validation of a dynamic contrast—enhanced magnetic resonance imaging—based habitat and peritumoral radiomic model to predict axillary lymph node metastasis in patients with breast cancer: a retrospective study[J]. Quantitative imaging in medicine and surgery, 2024, 14(12): 8211-8226.

[6] 尹柯, 陶俊利, 魏梅, 等. 生境成像用于肿瘤研究进展[J]. 中国医学影像技术, 2022, 38(9): 1421-1424.

[7] 古常燕, 聂芳. 超声造影应用于乳腺癌的新进展[J]. 兰州大学学报（医学版）, 2025, 51(3): 90-94.

[8] 贾燕茹, 柴军, 赵建华, 等. DCE—MRI影像组学联合临床特征鉴别luminal型与非luminal型乳腺癌的价值[J]. 中国CT和MRI杂志, 2024, 22(8): 63-66.

[9] 程卫群, 戚轩, 杨宏楷, 等. 基于多参数MR生境成像鉴别Luminal型和非Luminal型乳腺癌[J]. 磁共振成像, 2025, 16(5): 170-180.

[10] TOBALINA L, ARMENIA J, IRVING E, et al. A Meta—analysis of reversion mutations in BRCA genes identifies signatures of DNA end—joining repair mechanisms driving therapy resistance[J]. Annals of oncology, 2021, 32(1): 103-112.

[11] DU T M, ZHAO H D. Habitat analysis of breast cancer—enhanced MRI reflects BRCA1 mutation determined by immunohistochemistry[J]. BioMed research international, 2022, 2022(1): 9623173.

[12] DE NONNEVILLE A, HOUVENAEGHEL G, COHEN M, et al. Pathological complete response rate and disease—free survival after neoadjuvant chemotherapy in patients with HER2—low and HER2—0 breast cancers[J]. European journal of cancer, 2022, 176: 181-188.

[13] HU X E, YANG P, CHEN S H, et al. Clinical and biological heterogeneities in triple—negative breast cancer reveals a non—negligible role of HER2—low[J]. Breast cancer research, 2023, 25(1): 34.

[14] ZWANENBURG A, VALLIÈRES M, ABDALAH M A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high—throughput image—based phenotyping[J]. Radiology, 2020, 295(2): 328-338.

[15] NOHARA Y, MATSUMOTO K, SOEJIMA H, et al. Explanation of machine learning models using shapley additive explanation and application for real data in hospital[J]. Computer methods and programs in biomedicine, 2022, 214: 106584.

[16] CHEN H Q, LIU Y L, ZHAO J Q, et al. Quantification of intratumoral heterogeneity using habitat—based MRI radiomics to identify HER2—positive, low and zero breast cancers: a multicenter study[J]. Breast cancer research, 2024, 26(1): 160.

[17] ZHANG X L, CHEN X Y, FU Y, et al. Study on heterogeneity of vascularity and cellularity via multiparametric MRI habitat imaging in breast cancer[J]. BMC medical imaging, 2025, 25(1): 159.

[18] XU R, YU D, LUO P, et al. Do habitat MRI and fractal analysis help distinguish triple—negative breast cancer from non—triple—negative breast carcinoma[J]. Canadian association of radiologists journal, 2024, 75(3): 584-592.

[19] WAGLE N S, NOGUEIRA L, DEVASIA T P, et al. Cancer treatment and survivorship statistics, 2025[J]. Ca: a cancer journal for clinicians, 2025, 75(4): 308-340.

[20] MATIKAS A, KOTSAKIS A, APOSTOLAKI S, et al. Detection of circulating tumour cells before and following adjuvant chemotherapy and long—term prognosis of early breast cancer[J]. British journal of cancer, 2022, 126(11): 1563-1569.

[21] 张素鑫, 李海燕, 郑逸群, 等. 基于数字乳腺断层摄影的瘤内和瘤周影像组学对乳腺癌淋巴血管浸润状态的术前预测[J]. 实用放射学杂志, 2025, 41(1): 46-51.

[22] 孙玮, 李杰, 翟冬枝. 基于动态对比增强MRI影像组学支持向量机模型预测乳腺癌淋巴血管浸润状态的研究[J]. 实用放射学杂志, 2022, 38(11): 1795-1798.

[23] 程思佳, 翟晓阳, 周仕豪, 等. 基于术前MRI特征及定量参数列线图预测乳腺癌患者淋巴血管侵犯[J]. 磁共振成像, 2024, 15(5): 111-118.

[24] GE W, FAN X H, ZENG Y, et al. Exploring habitats—based spatial distributions: improving predictions of lymphovascular invasion in invasive breast cancer[J]. Academic radiology, 2024, 31(11): 4317-4328.

[25] CHEN S Y, ZHANG Y, SU Y Q, et al. Habitat radiomics based on dynamic contrast—enhanced magnetic resonance imaging for assessing axillary lymph node burden in clinical T1—T2 stage breast cancer: a multicenter and interpretable study[J]. Journal of magnetic resonance imaging, 2025, 62(3): 751-764.

[26] 丁佳, 黄碧云, 段庆红. 基于MR影像组学预测不同亚型乳腺癌新辅助化疗疗效[J]. 实用放射学杂志, 2024, 40(12): 1979-1983.

[27] ZHANG H, ZHENG Y Y, ZHANG M Z, et al. Breast Cancer: habitat imaging based on intravoxel incoherent motion for predicting pathologic complete response to neoadjuvant chemotherapy[J]. Medical physics, 2025, 52(6): 3711-3722.

[28] SYED A K, WHISENANT J G, BARNES S L, et al. Multiparametric analysis of longitudinal quantitative MRI data to identify distinct tumor habitats in preclinical models of breast cancer[J]. Cancers, 2020, 12(6): 1682.

[29] 程卫群, 戚轩, 杨宏楷, 等. 基于多参数MRI生境成像用于乳腺癌研究进展[J]. 中国医学影像技术, 2024, 40(11): 1798-1801.

[30] CHO H H, KIM H, NAM S Y, et al. Measurement of perfusion heterogeneity within tumor habitats on magnetic resonance imaging and its association with prognosis in breast cancer patients[J]. Cancers, 2022, 14(8): 1858.

[31] SHI Z W, HUANG X M, CHENG Z L, et al. MRI—based quantification of intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer[J]. Radiology, 2023, 308(1): e222830.

[32] BAKER S, LECHNER L, LIU M, et al. Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the phase 2 SABR—5 trial[J]. International journal of radiation oncology, biology, physics, 2024, 118(5): 1497-1506.

[33] VIANI G A, GOUVEIA A G, LOUIE A V, et al. Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta—analysis[J]. Radiotherapy and oncology, 2021, 164: 245-250.

[34] WEINFURTNER R J, ABDALAH M, STRINGFIELD O, et al. Quantitative changes in intratumoral habitats on MRI correlate with pathologic response in early—stage ER/PR+ HER2— breast cancer treated with preoperative stereotactic ablative body radiotherapy[J]. Journal of breast imaging, 2022, 4(3): 273-284.

基金资助

甘肃省自然科学基金项目(22JR11RA034)